Agios Pharmaceuticals, Inc.
AGIO US00847X1046
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -26% | -19% | -19% | 44% | 1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Scadden David |
40.00 USD |
200 Sold |
8,000 USD |
30/09/2025 | 30/09/2025 |
| Jones Cecilia CFO |
36.77 USD |
3,651 Sold |
134,247 USD |
26/09/2025 | 26/09/2025 |
| Washburn Theodore James Jr. CCO |
36.87 USD |
8,546 Sold |
315,091 USD |
05/09/2025 | 05/09/2025 |
| Scadden David |
40.00 USD |
200 Sold |
8,000 USD |
27/08/2025 | 27/08/2025 |
| Goff Brian CEO |
36.67 USD |
11,085 Sold |
406,487 USD |
08/08/2025 | 08/08/2025 |
| Scadden David |
40.00 USD |
1,400 Sold |
56,000 USD |
10/07/2025 | 10/07/2025 |
| Gheuens Sarah CMO |
38.76 USD |
847 Sold |
32,830 USD |
09/07/2025 | 09/07/2025 |
| Gheuens Sarah CMO |
37.93 USD |
11,067 Sold |
419,771 USD |
09/07/2025 | 09/07/2025 |
| Gheuens Sarah CMO |
34.17 USD |
4,091 Sold |
139,789 USD |
01/07/2025 | 01/07/2025 |
| Gheuens Sarah CMO |
33.54 USD |
2,909 Sold |
97,568 USD |
24/06/2025 | 24/06/2025 |